Kanabo Group PLC Partnership with BRITISH CANNABIS(TM)

TIDMKNB

Kanabo Group PLC

02 November 2023

2 November 2023

Kanabo Group Plc

("Kanabo", the "Group" or the "Company")

Partnership with BRITISH CANNABIS(TM)

Kanabo Group plc (LSE: KNB), the patient-focused provider of digital health services and specialist medicines, including medicinal cannabis, is pleased to announce that it has entered into a partnership with BRITISH CANNABIS(TM) to supply the CBD by BRITISH CANNABIS(TM) range of pharmacy-grade CBD health supplements to patients via a prescription service through the Group's online pain management clinic, Treat It .

The partnership will allow doctors to prescribe the CBD by BRITISH CANNABIS(TM) products to patients via the Treat It platform. Focused on secondary care, Treat It enables patients access to healthcare professionals via its secure, digital healthcare platform. These medical professionals deliver a full diagnosis as part of a personalised patient care plan and are able to offer treatments, including the prescription of medicinal cannabis, for individuals seeking relief from chronic pain. By incorporating CBD by BRITISH CANNABIS(TM) products into our offerings, Kanabo continues to increase the accessibility and affordability of high quality, alternative pain management solutions to improve overall patient quality of life.

From November, Treat It will also be included in Canndr, an online medicinal cannabis app from BRITISH CANNABIS(TM) which enables patients to select and review quality cannabis medicines on the market, gain consultancy advice and select from a number of suitable prescribing clinics.

Avihu Tamir, Chief Executive Officer of Kanabo, commented:

"At Kanabo, we aim to increase medicinal cannabis access for more patients. This partnership allows Treat It doctors to include a wider range of quality CBD supplements in our telemedicine offerings. We're eager to further enhance patient-centric healthcare and treatment options. This partnership is just the beginning, and we hope to announce more expansive collaborations in due course."

Steve Batchelor, BRITISH CANNABIS(TM) Marketing Director commented:

"We are thrilled to join forces with Treat It to make CBD products from our long-standing pharmacy retail brand accessible to pain patients through prescriptions. This partnership represents a significant step forward in expanding patient choices and empowering doctors to explore naturally-derived supplements, as alternatives to traditional pharmaceutical care paths.

"We are also pleased that thousands of long-term CBD customers will have the option to consult with Treat It's network of specialist pain doctors, assessing their own particular needs and determining things like what delivery formats, when and how much CBD they could be taking."

Enquiries:

 
Kanabo Group plc                                       via Vigo Consulting 
 Avihu Tamir, Chief Executive Officer                   [phone] 
 Assaf Vardimon, Chief Financial Officer 
 Ian Mattioli, Non-Executive Chair of the Board 
Peterhouse Capital Ltd (Financial Adviser) 
 Eran Zucker / Lucy Williams / Charles Goodfellow      [phone] 
Vigo Consulting (Financial Public Relations/Investor 
 Relations) 
 Jeremy Garcia / Fiona Hetherington / Verity 
 Snow                                                   [phone] 
 [e-mail]                               0230 
 

About BRITISH CANNABIS(TM)

BRITISH CANNABIS(TM) are pioneers in the UK cannabis industry since 2015, specialising in high-quality CBD products trusted by pharmacists and over 40,000 consumers alike. With over six years of experience and a strong reputation, BRITISH CANNABIS(TM) is dedicated to providing natural wellness solutions and promoting education surrounding CBD.

About Kanabo Group plc

Kanabo Group plc (LSE:KNB) is a digital health company committed to transforming patient care through its innovative technology platform and specialised treatment offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. Leveraging its telehealth capabilities, in February 2023, Kanabo launched Treat It - an online clinic focused on chronic pain management providing patients with secondary care.

With its two complementary business divisions, Kanabo has established itself as an end-to-end digital health provider, offering telehealth consultations, prescriptions, alongside the delivery of tailored treatments.

The Company's partially owned subsidiary, Kanabo Agritec Ltd, is a cultivation consultancy supporting cannabis businesses in developing new farms through infrastructural, research, and product guidance. These farms deliver high-quality raw materials for Kanabo's formulas and product line.

At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

Visit www.kanabogroup.com for more information.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABBBMTMTTMTRJ

(END) Dow Jones Newswires

November 02, 2023 03:00 ET (07:00 GMT)